Adenoviral vector immunity: Its implications and circumvention strategies

Current Gene Therapy

Volumn 11, Issue 4, 2011, Pages 307-320

  Ahi, Yadvinder S ^a   Bangari, Dinesh S ^b   Mittal, Suresh K ^a  

^a PURDUE UNIVERSITY   (United States)

^b GENZYME CORPORATION   (United States)

Author keywords

Adenoviral (Ad) vectors; Circumvention strategies; Gene delivery; Immunity; Serotypes; Therapeutic; Toxicity; Transgene expression; Vaccine

Indexed keywords

ADENOVIRUS VECTOR; ARGININE; ASPARTIC ACID; BLOOD CLOTTING FACTOR; CAPSID PROTEIN; CELL SURFACE RECEPTOR; CHEMOKINE; CLODRONIC ACID; COXSACKIE VIRUS AND ADENOVIRUS RECEPTOR; CYTOKINE; GADOLINIUM CHLORIDE; GLYCINE; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 6; LIPOSOME; MACROGOL; MANNAN; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; POLY[N (2 HYDROXYPROPYL)METHACRYLAMIDE]; POLYGLACTIN; PROTEIN C; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; VIRUS ANTIBODY; VIRUS FIBER PROTEIN; WARFARIN;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTATION; BOVINE ADENOVIRUS; CANINE ADENOVIRUS; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CELL INFILTRATION; CELL SURFACE; CELLULAR IMMUNITY; COMPLEMENT ACTIVATION; CYSTIC FIBROSIS; CYTOKINE RELEASE; DENDRITIC CELL; ENDOTHELIUM CELL; GENE SWITCHING; GENE TRANSFER; GENOTOXICITY; HELPER VIRUS; HUMAN; HUMAN ADENOVIRUS; HUMORAL IMMUNITY; HYPERTRANSAMINASEMIA; IMMUNE EVASION; IMMUNITY; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INNATE IMMUNITY; INOCULATION; KUPFFER CELL; LEUKOCYTE ACTIVATION; LIVER CELL; LIVER TOXICITY; MACROPHAGE; MEDIATOR RELEASE; MICROENCAPSULATION; MOLECULAR WEIGHT; NONHUMAN; PASSIVE IMMUNIZATION; PROTEIN FUNCTION; PROTEIN MODIFICATION; PROTEIN TARGETING; PSEUDOTYPING; REVIEW; SEROTYPE; THROMBOCYTOPENIA; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRAL GENETICS; VIRUS CAPSID; VIRUS CELL INTERACTION; VIRUS GENE; VIRUS INHIBITION; VIRUS LOAD; VIRUS TRANSMISSION;

ADENOVIRIDAE; ANIMALS; CAPSID; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HELPER VIRUSES; HUMANS; IMMUNITY, INNATE; IMMUNOSUPPRESSION; TRANSDUCTION, GENETIC; TRANSGENES; VACCINES;

EID: 79960015030     PISSN: 15665232     EISSN: 18755631     Source Type: Journal    
DOI: 10.2174/156652311796150372     Document Type: Review

References (224)

1. Paielli DL, Wing MS, Rogulski KR, et al. Evaluation of the biodistribution, persistence, toxicity, and potential of germ-line transmission of a replication-competent human adenovirus following intraprostatic administration in the mouse. Mol Ther 2000; 1: 263-274.
2. Bangari DS, Mittal SK. Porcine adenoviral vectors evade preexisting humoral immunity to adenoviruses and efficiently infect both human and murine cells in culture. Virus Res 2004; 105: 127-136.
3. Xiang Z, Li Y, Cun A, et al. Chimpanzee adenovirus antibodies in humans, sub-Saharan Africa. Emerg Infect Dis 2006; 12: 1596-1599.
4. Harvey BG, Worgall S, Ely S, Leopold PL, Crystal RG. Cellular immune responses of healthy individuals to intradermal administration of an E1-E3- adenovirus gene transfer vector. Hum Gene Ther 1999; 10: 2823-2837.
5. Dai Y, Schwarz EM, Gu D, et al. Cellular and humoral immuneresponses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression. Proc Natl Acad Sci USA 1995; 92: 1401-1405.
6. Elkon KB, Liu CC, Gall JG, et al. Tumor necrosis factor alpha plays a central role in immune-mediated clearance of adenoviral vectors. Proc Natl Acad Sci USA 1997; 94: 9814-9819.
7. Kafri T, Morgan D, Krahl T, et al. Cellular immune response to adenoviral vector infected cells does not require de novo viral gene expression: implications for gene therapy. Proc Natl Acad Sci USA 1998; 95: 11377-11382.
8. Yang Y, Nunes FA, Berencsi K, et al. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci USA 1994; 91: 4407-4411.
9. Yang Y, Li Q, Ertl HC, Wilson JM. Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J Virol 1995; 69: 2004-2015.
10. Toogood CI, Crompton J, Hay RT. Antipeptide antisera define neutralizing epitopes on the adenovirus hexon. J Gen Virol 1992; 73(Pt 6): 1429-1435.
11. Mittal SK, McDermott MR, Johnson DC, Prevec L, Graham FL. Monitoring foreign gene expression by a human adenovirus-based vector using the firefly luciferase gene as a reporter. Virus Res 1993; 28: 67-90.
12. Dong JY, Wang D, Van Ginkel FW, Pascual DW, Frizzell RA. Systematic analysis of repeated gene delivery into animal lungs with a recombinant adenovirus vector. Hum Gene Ther 1996; 7: 319-331.
13. Moffatt S, Hays J, HogenEsch H, Mittal SK. Circumvention of vector-specific neutralizing antibody response by alternating use of human and non-human adenoviruses: implications in gene therapy. Virology 2000; 272: 159-167.
14. Sailaja G, HogenEsch H, North A, Hays J, Mittal SK. Encapsulation of recombinant adenovirus into alginate microspheres circumvents vector-specific immune response. Gene Ther 2002; 9: 1722-1729.
15. Walter J, You Q, Hagstrom JN, Sands M, High KA. Successful expression of human factor IX following repeat administration of adenoviral vector in mice. Proc Natl Acad Sci USA 1996; 93:3056-3061.
16. Vlachaki MT, Hernandez-Garcia A, Ittmann M, et al. Impact of preimmunization on adenoviral vector expression and toxicity in a subcutaneous mouse cancer model. Mol Ther 2002; 6: 342-348.
17. Varnavski AN, Zhang Y, Schnell M, et al. Preexisting immunity to adenovirus in rhesus monkeys fails to prevent vector-induced toxicity. J Virol 2002; 76: 5711-5719.
18. Varnavski AN, Calcedo R, Bove M, Gao G, Wilson JM. Evaluation of toxicity from high-dose systemic administration of recombinant adenovirus vector in vector-naive and pre-immunized mice. Gene Ther 2005; 12: 427-436.
19. Perreau M, Pantaleo G, Kremer EJ. Activation of a dendritic cell-T cell axis by Ad5 immune complexes creates an improved environment for replication of HIV in T cells. J Exp Med 2008; 205: 2717- 2725.
20. Zaiss AK, Vilaysane A, Cotter MJ, et al. Antiviral antibodies target adenovirus to phagolysosomes and amplify the innate immune response. J Immunol 2009; 182: 7058-7068.
21. Tang J, Olive M, Pulmanausahakul R, et al. Human CD8+ cytotoxic T cell responses to adenovirus capsid proteins. Virology 2006; 350: 312-322.
22. Olive M, Eisenlohr L, Flomenberg N, Hsu S, Flomenberg P. The adenovirus capsid protein hexon contains a highly conserved human D4+ T-cell epitope. Hum Gene Ther 2002; 13: 1167-1178.
23. Crystal RG. Transfer of genes to humans: early lessons and obstacles to success. Science 1995; 20; 270: 404-410.
24. Appledorn DM, McBride A, Seregin S, et al. Complex interactions with several arms of the complement system dictate innate and humoralimmunity to adenoviral vectors. Gene Ther 2008; 15: 1606-1617.
25. Tian J, Xu Z, Smith JS, et al. Adenovirus activates complement by distinctly different mechanisms in vitro and in vivo: indirect complement activation by virions in vivo. J Virol 2009; 83: 5648-5658.
26. Xu Z, Tian J, Smith JS, Byrnes AP. Clearance of adenovirus by Kupffer cells is mediated by scavenger receptors, natural antibodies, and complement. J Virol 2008; 82: 11705-17713.
27. Kiang A, Hartman ZC, Everett RS, et al. Multiple innate inflammatory responses induced after systemic adenovirus vector delivery depend on a functional complement system. Mol Ther 2006; 14: 588-598.
28. Greig JA, Buckley SM, Waddington SN, et al. Influence of coagulation factor x on in vitro and in vivo gene delivery by adenovirus (Ad) 5, Ad35, and chimeric Ad5/Ad35 vectors. Mol Ther 2009; 17: 1683-1691.
29. Parker AL, Waddington SN, Nicol CG, et al. Multiple vitamin Kdependent coagulation zymogens promote adenovirus-mediated gene delivery to hepatocytes. Blood 2006; 108: 2554-2561.
30. Shayakhmetov DM, Gaggar A, Ni S, Li ZY, Lieber A. Adenovirus binding to blood factors results in liver cell infection and hepatotoxicity. J Virol 2005; 79: 7478-7491.
31. Rhee EG, Blattman JN, Kasturi SP, et al. Multiple innate immune pathways contribute to the immunogenicity of recombinant adenovirus vaccine vectors. J Virol 2011; 85: 315-323.
32. Jiang H, Wang Z, Serra D, Frank MM, Amalfitano A. Recombinant adenovirus vectors activate the alternative complement pathway, leading to the binding of human complement protein C3 independent of anti-ad antibodies. Mol Ther 2004; 10: 1140-1142.
33. Cichon G, Boeckh-Herwig S, Schmidt HH, et al. Complement activation by recombinant adenoviruses. Gene Therapy 2001; 8: 1794-1800.
34. Cerullo V, Seiler MP, Mane V, et al. Toll-like receptor 9 triggers an innate immune response to helper-dependent adenoviral vectors. Mol Ther 2007; 15: 378-385.
35. Zaiss AK, Liu Q, Bowen GP, et al. Differential activation of innate immune responses by adenovirus and adeno-associated virus vectors. J Virol 2002; 76: 4580-4590.
36. Segura MM, Alba R, Bosch A, Chillon M. Advances in helperdependent adenoviral vector research. Current Gene Therapy 2008; 8: 222-235.
37. Liu Q, Zaiss AK, Colarusso P, et al. The role of capsid-endothelial interactions in the innate immune response to adenovirus vectors. Hum Gene Ther 2003; 14: 627-643.
38. Brenner M. Gene transfer by adenovectors. Blood 1999; 94: 3965-3967.
39. Seiler MP, Cerullo V, Lee B. Immune response to helper dependent adenoviral mediated liver gene therapy: challenges and prospects. Curr Gene Ther 2007; 7: 297-305.
40. Schiedner G, Bloch W, Hertel S, et al. A hemodynamic response to intravenous adenovirus vector particles is caused by systemic Kupffer cell-mediated activation of endothelial cells. Hum Gene Ther 2003; 14: 1631-1641.
41. Wolins N, Lozier J, Eggerman TL, et al. Intravenous administration of replication-incompetent adenovirus to rhesus monkeys induces thrombocytopenia by increasing in vivo platelet clearance. Br J Haematol 2003; 123: 903-905.
42. Morral N, O'Neal WK, Rice K, et al. Lethal toxicity, severe endothelial injury, and a threshold effect with high doses of an adenoviral vector in baboons. Hum Gene Ther 2002; 13: 143-154.
43. Schnell MA, Zhang Y, Tazelaar J, et al. Activation of innate immunity in nonhuman primates following intraportal administration of adenoviral vectors. Mol Ther 2001; 3: 708-722.
44. Zhang Y, Chirmule N, Gao GP, et al. Acute cytokine response to systemic adenoviral vectors in mice is mediated by dendritic cells and macrophages. Mol Ther 2001; 3: 697-707.
45. Smith JS, Tian J, Muller J, Byrnes AP. Unexpected pulmonary uptake of adenovirus vectors in animals with chronic liver disease. Gene Ther 2004; 11: 431-438.
46. Smith JS, Tian J, Lozier JN, Byrnes AP. Severe pulmonary pathology after intravenous administration of vectors in cirrhotic rats. Mol Ther 2004; 9: 932-941.
47. Stilwell JL, McCarty DM, Negishi A, Superfine R, Samulski RJ. Development and characterization of novel empty adenovirus capsids and their impact on cellular gene expression. J Virol 2003; 77: 12881-12885.
48. Bramson JL, Hitt M, Gauldie J, Graham FL. Pre-existing immunity to adenovirus does not prevent tumor regression following intratumoral administration of a vector expressing IL-12 but inhibits virus dissemination. Gene Ther 1997; 4: 1069-10676.
49. Nagao S, Kuriyama S, Okuda H, et al. Adenovirus-mediated gene transfer into tumors: evaluation of direct readministration of an adenoviral vector into subcutaneous tumors of immunocompetent mice. Int J Oncol 2001; 18: 57-65.
50. Nunes FA, Furth EE, Wilson JM, Raper SE. Gene transfer into the liver of nonhuman primates with E1-deleted recombinant adenoviral vectors: safety of readministration. Hum Gene Ther 1999; 10: 2515-2526.
51. Brunetti-Pierri N, Ng P. Progress towards liver and lung-directed gene therapy with helper-dependent adenoviral vectors. Curr Gene Ther 2009; 9: 329-340.
52. Wilmott RW, Amin RS, Perez CR, et al. Safety of adenovirusmediated transfer of the human cystic fibrosis transmembrane conductance regulator cDNA to the lungs of nonhuman primates. Hum Gene Ther 1996; 7: 301-318.
53. Ginsberg HS, Moldawer LL, Sehgal PB, et al. A mouse model for investigating the molecular pathogenesis of adenovirus pneumonia. Proc Natl Acad Sci U S A 1991; 88: 1651-1655.
54. Prince GA, Porter DD, Jenson AB, et al. Pathogenesis of adenovirus type 5 pneumonia in cotton rats (Sigmodon hispidus). J Virol 1993; 67: 101-111.
55. Li Y, Shao JY, Liu RY, et al. Evaluation of long-term toxicity of Ad/hIFN-gamma, an adenoviral vector encoding the human interferon- gamma gene, in nonhuman primates. Human Gene Therapy 2008; 19: 827-839.
56. Huang BJ, Liu RY, Huang JL, et al. Long-term toxicity studies in canine of E10A, an adenoviral vector for human endostatin gene. Human Gene Therapy 2007; 18: 207-221.
57. Maione D, Della RC, Giannetti P, et al. An improved helperdependent adenoviral vector allows persistent gene expression after intramuscular delivery and overcomes preexisting immunity to adenovirus. Proc Natl Acad Sci USA 2001; 98: 5986-5991.
58. Seregin SS, Appledorn DM, McBride AJ, et al. Transient pretreatment with glucocorticoid ablates innate toxicity of systemically delivered adenoviral vectors without reducing efficacy. Mol Ther 2009; 17: 685-696.
59. Thomas MA, Spencer JF, Toth K, et al. Immunosuppression enhances oncolytic adenovirus replication and antitumor efficacy in the Syrian hamster model. Mol Ther 2008; 16: 1665-16973.
60. Smith TA, White BD, Gardner JM, Kaleko M, McClelland A. Transient immunosuppression permits successful repetitive intravenousadministration of an adenovirus vector. Gene Ther 1996; 3: 496-502.
61. Kaplan JM, Smith AE. Transient immuno suppression with deo xyspergualin improves longevity of transgene expression and ability to read minister adenoviral vector to the mouse lung. Hum Gene Ther 1997; 8: 1095-1104.
62. Ilan Y, Jona VK, Sengupta K, et al. Transient immuno suppression with FK506 permits long-term expression of therapeutic genes introduced into the liver using recombinant adenoviruses in the rat. Hepatology 1997; 26: 949-956.
63. Guerette B, Vilquin JT, Gingras M, et al. Prevention of immune reactions triggered by first-generation adenoviral vectors by monoclonal antibodies and CTLA4Ig. Hum Gene Ther 1996; 7: 1455-1463.
64. Jooss K, Turka LA, Wilson JM. Blunting of immune responses to adenoviral vectors in mouse liver and lung with CTLA4Ig. Gene Ther 1998; 5: 309-319.
65. Ye X, Robinson MB, Pabin C, Batshaw ML, Wilson JM. Transient depletion of CD4 lymphocyte improves efficacy of repeated administration of recombinant adenovirus in the ornithine transcarbamylase deficient sparse fur mouse. Gene Ther 2000; 7: 1761-1771.
66. Chirmule N, Raper SE, Burkly L, et al. Readministration of adenovirus vector in nonhuman primate lungs by blockade of CD40-CD40 ligand interactions. J Virol 2000; 74: 3345-3352.
67. Haegel-Kronenberger H, Haanstra K, Ziller-Remy C, et al. Inhibition of costimulation allows for repeated systemic administration of adenoviral vector in rhesus monkeys. Gene Ther 2004; 11: 241-252.
68. Ilan Y, Sauter B, Chowdhury NR, et al. Oral tolerization to adenoviral proteins permits repeated adenovirus-mediated gene therapy in rats with pre-existing immunity to adenoviruses. Hepatology 1998; 27: 1368-1376.
69. Fontanellas A, Hervas-Stubbs S, Mauleon I, et al. Intensive pharmacological immunosuppression allows for repetitive liver gene transfer with recombinant adenovirus in nonhuman primates. Mol Ther 2010; 18: 754-765.
70. Dhar D, Spencer JF, Toth K, Wold WS. Pre-existing immunity and passive immunity to adenovirus 5 prevents toxicity caused by an oncolytic adenovirus vector in the Syrian hamster model. Mol Ther 2009; 17: 1724-1732.
71. Peng Y, Trevejo J, Zhou J, et al. Inhibition of tumor necrosis factor alpha by an adenovirus-encoded soluble fusion protein extends transgene expression in the liver and lung. J Virol 1999; 73: 5098-5109.
72. Benihoud K, Esselin S, Descamps D, et al. Respective roles of TNF-alpha and IL-6 in the immune response-elicited by adenovirus- mediated gene transfer in mice. Gene Ther 2007; 14: 533-544.
73. Wilderman MJ, Kim S, Gillespie CT, et al. Blockade of TNF-alpha decreases both inflammation and efficacy of intrapulmonary Ad. IFNbeta immunotherapy in an orthotopic model of bronchogenic lung cancer. Mol Ther 2006; 13: 910-917.
74. Sakurai H, Tashiro K, Kawabata K, et al. Adenoviral expression of suppressor of cytokine signaling-1 reduces adenovirus vectorinduced innate immune responses. J Immunol 2008; 180: 4931-4938.
75. Shayakhmetov DM, Li ZY, Ni S, Lieber A. Interference with the IL-1-signaling pathway improves the toxicity profile of systemically applied adenovirus vectors. J Immunol 2005; 174: 7310-7319.
76. Worgall S, Leopold PL, Wolff G, et al. Role of alveolar macrophages in rapid elimination of adenovirus vectors administered to the epithelial surface of the respiratory tract. Hum Gene Ther 1997; 8: 1675-1684.
77. Lieber A, He CY, Meuse L, et al. The role of Kupffer cell activation and viral gene expression in early liver toxicity after infusion of recombinant adenovirus vectors. J Virol 1997; 71: 8798-807.
78. Kuzmin AI, Finegold MJ, Eisensmith RC. Macrophage depletion increases the safety, efficacy and persistence of adenovirusmediated gene transfer in vivo. Gene Therapy 1997; 4: 309-316.
79. Schiedner G, Hertel S, Johnston M, et al. Selective depletion or blockade of Kupffer cells leads to enhanced and prolonged hepatic transgene expression using high-capacity adenoviral vectors. Mol Ther 2003; 7: 35-43.
80. Shashkova EV, Doronin K, Senac JS, Barry MA. Macrophage depletion combined with anticoagulant therapy increases therapeutic window of systemic treatment with oncolytic adenovirus. Cancer Res 2008; 68: 5896-5904.
81. Haisma HJ, Kamps JA, Kamps GK, et al. Polyinosinic acid enhances delivery of adenovirus vectors in vivo by preventing sequestration in liver macrophages. J Gen Virol 2008; 89: 1097-1105.
82. Haisma HJ, Boesjes M, Beerens AM, et al. Scavenger receptor A: a new route for adenovirus 5. Mol Pharm 2009; 6: 366-374.
83. Stone D, Liu Y, Shayakhmetov D, et al. Adenovirus-platelet interaction in blood causes virus sequestration to the reticuloendothelial system of the liver. J Virol 2007; 81: 4866-4871.
84. Kreppel F, Kochanek S. Modification of adenovirus gene transfer vectors with synthetic polymers: a scientific review and technical guide. Mol Ther 2008; 16: 16-29.
85. Croyle MA, Yu QC, Wilson JM. Development of a rapid method for the PEGylation of adenoviruses with enhanced transduction and improved stability under harsh storage conditions. Hum Gene Ther 2000; 11: 1713-1722.
86. Croyle MA, Chirmule N, Zhang Y, Wilson JM. PE Gylation of E1- deleted adenovirus vectors allows significant gene expression on readministration to liver. Hum Gene Ther 2002; 13: 1887-900.
87. Lanciotti J, Song A, Doukas J, et al. Targeting adenoviral vectors using heterofunctional polyethylene glycol FGF2 conjugates. Molecular Therapy 2003; 8: 99-107.
88. O'Riordan CR, Lachapelle A, Delgado C, et al. PE Gylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo. Hum Gene Ther 1999; 10: 1349-1358.
89. Fisher KD, Stallwood Y, Green NK, et al. Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies. Gene Ther 2001; 8: 341-348
90. Espenlaub S, Wortmann A, Engler T, et al. Reductive amination as a strategy to reduce adenovirus vector promiscuity by chemical capsid modification with large polysaccharides. J Gene Med 2008; 10: 1303-1313.
91. Eto Y, Yoshioka Y, Ishida T, et al. Optimized PEGylated adenovirus vector reduces the anti-vector humoral immune response against adenovirus and induces a therapeutic effect against metastatic lung cancer. Biol Pharm Bull 2010; 33: 1540-1544
92. Eto Y, Gao JQ, Sekiguchi F, et al. PEGylated adenovirus vectors containing RGD peptides on the tip of PEG show high transduction efficiency and antibody evasion ability. J Gene Med 2005; 7: 604-612.
93. Croyle MA, Chirmule N, Zhang Y, Wilson JM. Stealth adenoviruses blunt cell-mediated and humoral immune responses against the virus and allow for significant gene expression upon readministration in the lung. J Virol 2001; 75: 4792-4801.
94. Geest BD, Snoeys J, Linthout SV, Lievens J, Collen D. Elimination of Innate Immune Responses and Liver Inflammation by PEGylation of Adenoviral Vectors and Methylprednisolone. Hum Gene Ther 2005; 16: 1439-1451.
95. Mok H, Palmer DJ, Ng P, Barry MA. Evaluation of polyethylene glycol modification of first-generation and helper-dependent adenoviral vectors to reduce innate immune responses. Molecular Therapy 2005; 11: 66-79.
96. Croyle MA, Le HT, Linse KD, et al. PEGylated helper-dependent adenoviral vectors: highly efficient vectors with an enhanced safety profile. Gene Ther 2005; 12: 579-587.
97. Wortmann A, Vohringer S, Engler T, et al. Fully detargeted polyethylene glycol-coated adenovirus vectors are potent genetic vaccines and escape from pre-existing anti-adenovirus antibodies. Mol Ther 2008; 16: 154-162.
98. Park JW, Mok H, Park TG. Epidermal growth factor (EGF) receptor targeted delivery of PEGylated adenovirus. Biochem Biophys Res Commun 2008; 366: 769-774.
99. Jung Y, Park HJ, Kim PH, et al. Retargeting of adenoviral gene delivery via Herceptin-PEG-adenovirus conjugates to breast cancer cells. J Control Release 2007; 123: 164-171.
100. Ogawara K, Rots MG, Kok RJ, et al. A novel strategy to modify adenovirus tropism and enhance transgene delivery to activated vascular endothelial cells in vitro and in vivo. Hum Gene Ther 2004; 15: 433-443.
101. Morrison J, Briggs SS, Green NK, et al. Cetuximab retargeting of adenovirus via the epidermal growth factor receptor for treatment of intraperitoneal ovarian cancer. Hum Gene Ther 2009; 20: 239-251.
102. Green NK, Morrison J, Hale S, et al. Retargeting polymer-coated adenovirus to the FGF receptor allows productive infection and mediates efficacy in a peritoneal model of human ovarian cancer. J Gene Med 2008; 10: 280-289.
103. Green NK, Herbert CW, Hale SJ, et al. Extended plasma circulation time and decreased toxicity of polymer-coated adenovirus. Gene Ther 2004; 11: 1256-1263.
104. Bergelson JM, Cunningham JA, Droguett G, et al. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 1997; 275: 1320-1323.
105. Tomko RP, Xu R, Philipson L. HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. Proc Natl Acad Sci USA 1997; 94: 3352-3356.
106. Roelvink PW, Lizonova A, Lee JG, et al. The coxsackievirusadenovirusreceptor protein can function as a cellular attachment protein for adenovirus serotypes from subgroups A, C, D, E, and F. J Virol 1998; 72: 7909-7915.
107. Gaggar A, Shayakhmetov DM, Lieber A. CD46 is a cellular receptor for group B adenoviruses. Nat Med 2003; 9: 1408-1412.
108. Tuve S, Wang H, Ware C, et al. A new group B adenovirus receptor is expressed at high levels on human stem and tumor cells. J Virol 2006; 80: 12109-12120.
109. Short JJ, Pereboev AV, Kawakami Y, et al. Adenovirus serotype 3 utilizes CD80 (B7.1) and CD86 (B7.2) as cellular attachment receptors. Virology 2004; 322: 349-359.
110. Hong SS, Karayan L, Tournier J, Curiel DT, Boulanger PA. Adenovirus type 5 fiber knob binds to MHC class I alpha2 domain at the surface of human epithelial and B lymphoblastoid cells. EMBO J 1997; 16: 2294-2306.
111. Smith KD, Andersen-Nissen E, Hayashi F, et al. Toll-like receptor 5 recognizes a conserved site on flagellin required for protofilament formation and bacterial motility. Nat Immunol 2003; 4: 1247-1253.
112. Arnberg N, Edlund K, Kidd AH, Wadell G. Adenovirus type 37 uses sialic acid as a cellular receptor. J Virol 2000; 74: 42-48.
113. Wickham TJ, Mathias P, Cheresh DA, Nemerow GR. Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell 1993; 73: 309-319.
114. Bai M, Harfe B, Freimuth P. Mutations that alter an Arg-Gly-Asp (RGD) sequence in the adenovirus type 2 penton base protein abolish its cell-rounding activity and delay virus reproduction in flat cells. J Virol 1993; 67: 5198-51205.
115. Li E, Brown SL, Stupack DG, et al. Integrin alpha(v)beta1 is an adenovirus coreceptor. J Virol 2001; 75: 5405-5409.
116. Bilbao G, Gomez-Navarro J, Curiel DT. Targeted adenoviral vectors for cancer gene therapy. Adv Exp Med Biol 1998; 451:365-374.
117. Curiel DT. Strategies to adapt adenoviral vectors for targeted delivery. Ann N Y Acad Sci 1999; 886:158-171.
118. Douglas JT, Rogers BE, Rosenfeld ME, et al. Targeted gene delivery by tropism-modified adenoviral vectors. Nat Biotechnol 1996; 14: 1574-1578.
119. Gu DL, Gonzalez AM, Printz MA, et al. Fibroblast growth factor 2 retargeted adenovirus has redirected cellular tropism: evidence for reduced toxicity and enhanced antitumor activity in mice. CancerRes 1999; 59: 2608-2614.
120. Krasnykh V, Dmitriev I, Mikheeva G, et al. Characterization of an adenovirus vector containing a heterologous peptide epitope in the HI loop of the fiber knob. J Virol 1998; 72: 1844-18452.
121. Li HJ, Everts M, Pereboeva L, et al. Adenovirus tumor targeting and hepatic untargeting by a coxsackie/adenovirus receptor ectodomain anti-carcinoembryonic antigen bispecific adapter. Cancer Res 2007; 67: 5354-53561.
122. Molinier-Frenkel V, Prevost-Blondel A, Hong SS, et al. The maturation of murine dendritic cells induced by human adenovirus is mediated by the fiber knob domain. J Biol Chem 2003; 278: 37175-37182.
123. Myhre S, Henning P, Granio O, et al. Decreased immune reactivity towards a knobless, affibody-targeted adenovirus type 5 vector. Gene Ther 2007; 14: 376-381.
124. Schoggins JW, Nociari M, Philpott N, Falck-Pedersen E. Influence of fiber detargeting on adenovirus-mediated innate and adaptive immune activation. J Virol 2005; 79: 11627-11637.
125. Nanda A, Lynch DM, Goudsmit J, et al. Immunogenicity of recombinant fiber-chimeric adenovirus serotype 35 vector-based vaccines in mice and rhesus monkeys. J Virol 2005; 79: 14161-14168.
126. Rogee S, Grellier E, Bernard C, et al. Influence of chimeric humanbovine fibers on adenoviral uptake by liver cells and the antiviral immune response. Gene Ther 2010; 17: 880-891.
127. Ostapchuk P, Hearing P. Pseudopackaging of adenovirus type 5 genomes into capsids containing the hexon proteins of adenovirus serotypes B, D, or E. J Virol 2001; 75: 45-51.
128. Sumida SM, Truitt DM, Lemckert AA, et al. Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein. J Immunol 2005; 174: 7179-7185.
129. Waddington SN, McVey JH, Bhella D, et al. Adenovirus serotype 5 hexon mediates liver gene transfer. Cell 2008; 132: 397-409.
130. Alba R, Bradshaw AC, Coughlan L, et al. Biodistribution and retargeting of FX-binding ablated adenovirus serotype 5 vectors. Blood 2010; 116: 2656-2664.
131. Kim J, Smith T, Idamakanti N, et al. Targeting adenoviral vectors by using the extracellular domain of the coxsackie-adenovirus receptor: improved potency via trimerization. J Virol 2002; 76: 1892-1903.
132. Aoki Y, Hosaka S, Kawa S, Kiyosawa K. Potential tumor-targeting peptide vector of histidylated oligolysine conjugated to a tumorhoming RGD motif. Cancer Gene Ther 2001; 8: 783-787.
133. Belousova N, Krendelchtchikova V, Curiel DT, Krasnykh V. Modulation of adenovirus vector tropism via incorporation of polypeptide ligands into the fiber protein. J Virol 2002; 76: 8621-8631.
134. iermann V, Volpers C, Hussmann S, et al. Targeting of highcapacity adenoviral vectors. Hum Gene Ther 2001; 12: 1757-1769.
135. Douglas JT, Miller CR, Kim M, et al. A system for the propagation of adenoviral vectors with genetically modified receptor specificities. Nat Biotechnol 1999; 17: 470-475.
136. Mizuguchi H, Koizumi N, Hosono T, et al. A simplified system for constructing recombinant adenoviral vectors containing heterologous peptides in the HI loop of their fiber knob. Gene Ther 2001; 8:730-735.
137. Nicklin SA, Von Seggern DJ, Work LM, et al. Ablating adenovirus type 5 fiber-CAR binding and HI loop insertion of the SIGYPLP peptide generate an endothelial cell-selective adenovirus. Mol Ther 2001; 4: 534-542.
138. Dmitriev IP, Kashentseva EA, Curiel DT. Engineering of adenovirus vectors containing heterologous peptide sequences in the C terminus of capsid protein IX. J Virol 2002; 76: 6893-6899.
139. Zakhartchouk A, Connors W, van KA, Tikoo SK. Bovine adenovirus type 3 containing heterologous protein in the C-terminus of minor capsid protein IX. Virology 2004; 320: 291-300.
140. Krasnykh V, Belousova N, Korokhov N, Mikheeva G, Curiel DT. Genetic targeting of an adenovirus vector via replacement of the fiber protein with the phage T4 fibritin. J Virol 2001; 75: 4176-4183.
141. Chillon M, Lee JH, Fasbender A, Welsh MJ. Adenovirus complexed with polyethylene glycol and cationic lipid is shielded from neutralizing antibodies in vitro. Gene Ther 1998; 5: 995-1002.
142. Beer SJ, Matthews CB, Stein CS, et al. Poly (lactic-glycolic) acid opolymer encapsulation of recombinant adenovirus reduces immunogenicity in vivo. Gene Ther 1998; 5: 740-746.
143. Mok H, Park JW, Park TG. Microencapsulation of PEGylated adenovirus within PLGA microspheres for enhanced stability and gene transfection efficiency. Pharm Res 2007; 24: 2263-2269.
144. Wang D, Molavi O, Lutsiak ME, et al. Poly(D,L-lactic-co-glycolic acid) microsphere delivery of adenovirus for vaccination. J Pharm Pharm Sci 2007; 10: 217-230.
145. Garcia del BG, Hendry J, Renedo MJ, Irache JM, Novo FJ. In vivo sustained release of adenoviral vectors from poly(D,L-lactic-coglycolic) acid microparticles prepared by TROMS. J Control Release 2004; 94: 229-235.
146. Han SY, Lee YJ, Jung HI, et al. Gene transfer using liposomecomplexed adenovirus seems to overcome limitations due to coxsackievirus and adenovirus receptor-deficiency of cancer cells, both in vitro and in vivo. Exp Mol Med 2008; 40: 427-434.
147. Fukuhara H, Hayashi Y, Yamamoto N, et al. Improvement of transduction efficiency of recombinant adenovirus vector conjugated with cationic liposome for human oral squamous cell carcinoma cell lines. Oral Oncol 2003; 39: 601-609.
148. Cao M, Deng HX, Zhao J, et al. Antitumour activity of cationicliposome- conjugated adenovirus containing the CCL19 [chemokine (C-C motif) ligand 19] gene. Biotechnol Appl Biochem 2007; 48: 109-116.
149. Zhong Z, Shi S, Han J, Zhang Z, Sun X. Anionic liposomes increase the efficiency of adenovirus-mediated gene transfer to coxsackie-adenovirus receptor deficient cells. Mol Pharm 2010; 7: 105-115.
150. Yotnda P, Chen DH, Chiu W, et al. Bilamellar cationic liposomes protect adenovectors from preexisting humoral immune responses. Mol Ther 2002; 5: 233-241.
151. Steel JC, Cavanagh HM, Burton MA, Kalle WH. Micro sphereliposome complexes protect adenoviral vectors from neutralizing antibody without losses in transfection efficiency, in-vitro. J Pharm Pharmacol 2004; 56: 1371-1378.
152. Aggarwal N, HogenEsch H, Guo P, et al. Biodegradable alginate microspheres as a delivery system for naked DNA. Can J Vet Res 1999; 63: 148-152.
153. Bowerstock T.L., HogenEsch H, Suckow M, et al. Oral vaccination of animals with antigens encapsulated in alginate microspheres. Vaccine 1999; 17: 1804-1811.
154. Hilbert AK, Fritzsche U, Kissel T. Biodegradable microspheres containing influenza A vaccine: immune response in mice. Vaccine 1999; 17: 1065-1073.
155. Mittal SK, Aggarwal N, Sailaja G, et al. Immunization with DNA, adenovirus or both in biodegradable alginate microspheres: effect of route of inoculation on immune response. Vaccine 2000; 19: 253-263.
156. Periwal SB, Speaker TJ, Cebra JJ. Orally administered microencapsulated reovirus can bypass suckled, neutralizing maternal antibody that inhibits active immunization of neonates. J Virol 1997; 71: 2844-2850.
157. Lomotan EA, Brown KA, Speaker TJ, Offita PA. Aqueous-based microcapsules are detected primarily in gut-associated dendritic cells after oral inoculation of mice. Vaccine 1997; 15: 1959-1960
158. Yang D, Jones KS. Effect of alginate on innate immune activation of macrophages. Journal of Biomedical Materials Research Part A 2009; 90A: 411-418.
159. Engelhardt JF, Ye X, Doranz B, Wilson JM. Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver. Proc Natl Acad Sci USA 1994; 91: 6196-6200.
160. Fisher KJ, Choi H, Burda J, Chen SJ, Wilson JM. Recombinant adenovirus deleted of all viral genes for gene therapy of cystic fibrosis. Virology 1996; 217: 11-22.
161. Kochanek S, Clemens PR, Mitani K, et al. A new adenoviral vector: Replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and betagalactosidase. Proc Natl Acad Sci USA 1996; 93: 5731-6.
162. Morsy MA, Gu M, Motzel S, et al. An adenoviral vector deleted for all viral coding sequences results in enhanced safety and extended expression of a leptin transgene. Proc Natl Acad Sci USA 1998; 95: 7866-7871.
163. Parks R, Chen L, Anton M, et al. A new helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal. Proc Natl Acad Sci USA 1996; 93: 13565-13570.
164. Schiedner G, Morral N, Parks RJ, et al. Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity. Nat Genet 1998; 18: 180-183.
165. Morral N, Parks RJ, Zhou H, et al. High doses of a helperdependent adenoviral vector yield supraphysiological levels of alpha1-antitrypsin with negligible toxicity. Hum Gene Ther 1998; 9: 2709-2716.
166. Morral N, O'Neal W, Rice K, et al. Administration of helperdependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons. Proc Natl Acad Sci USA 1999; 96: 12816-12821.
167. Roth MD, Cheng Q, Harui A, et al. Helper-dependent adenoviral vectors efficiently express transgenes in human dendritic cells but still stimulate antiviral immune responses. J Immunol 2002; 169: 4651-4656.
168. Muruve DA, Cotter MJ, Zaiss AK, et al. Helper-dependent adenovirus vectors elicit intact innate but attenuated adaptive host immune responses in vivo. J Virol 2004; 78: 5966-5972.
169. Brunetti-Pierri N, Ng T, Iannitti DA, et al. Improved hepatic transduction, reduced systemic vector dissemination, and long-term transgene expression by delivering helper-dependent adenoviral vectors into the surgically isolated liver of nonhuman primates. Hum Gene Ther 2006; 17: 391-404.
170. Brunetti-Pierri N, Nichols TC, McCorquodale S, et al. Sustained phenotypic correction of canine hemophilia B after systemic administration of helper-dependent adenoviral vector. Hum Gene Ther 2005; 16: 811-820.
171. Toietta G, Mane VP, Norona WS, et al. Lifelong elimination of hyperbilirubinemia in the Gunn rat with a single injection of helper-dependent adenoviral vector. Proc Natl Acad Sci U S A 2005; 102: 3930-5.
172. Brown BD, Shi CX, Powell S, et al. Helper-dependent adenoviral vectors mediate therapeutic factor VIII expression for several months with minimal accompanying toxicity in a canine model of severe hemophilia A. Blood 2004; 103: 804-810.
173. Kim IH, Jozkowicz A, Piedra PA, Oka K, Chan L. Lifetime correction of genetic deficiency in mice with a single injection of helperdependent adenoviral vector. Proc Natl Acad Sci USA 2001; 98: 13282-13287.
174. Palmer DJ, Ng P. Helper-dependent adenoviral vectors for gene therapy. Hum Gene Ther 2005; 16: 1-16.
175. Bilbao R, Reay DP, Wu E, et al. Comparison of high-capacity and first-generation adenoviral vector gene delivery to murine muscle in utero. Gene Ther 2005; 12: 39-47.
176. Recchia A, Perani L, Sartori D, Olgiati C, Mavilio F. Site-specific integration of functional transgenes into the human genome by adeno/AAV hybrid vectors. Mol Ther 2004; 10: 660-670.
177. Dorigo O, Gil JS, Gallaher SD, et al. Development of a novel helper-dependent adenovirus-Epstein-Barr virus hybrid system for the stable transformation of mammalian cells. J Virol 2004; 78: 6556-6566.
178. Ehrhardt A, Yant SR, Giering JC, et al. Somatic integration from an adenoviral hybrid vector into a hot spot in mouse liver results in persistent transgene expression levels in vivo. Mol Ther 2007; 15: 146-156.
179. King GD, Muhammad AK, Xiong W, et al. High-capacity adenovirus vector-mediated anti-glioma gene therapy in the presence of systemic antiadenovirus immunity. J Virol 2008; 82: 4680-4684.
180. Barcia C, Jimenez-Dalmaroni M, Kroeger KM, et al. One-year expression from high-capacity adenoviral vectors in the brains of animals with pre-existing anti-adenoviral immunity: clinical implications. Mol Ther 2007; 15: 2154-2163.
181. Xiong W, Goverdhana S, Sciascia SA, et al. Regulatable Gutless Adenovirus Vectors Sustain Inducible Transgene Expression in theBrain in the Presence of an Immune Response against Adenoviruses.J Virol 2006; 80: 27-37.
182. Thomas CE, Schiedner G, Kochanek S, Castro MG, Lowenstein PR. Peripheral infection with adenovirus causes unexpected longterm brain inflammation in animals injected intracranially with first-generation, but not with high-capacity, adenovirus vectors: toward realistic long-term neurological gene therapy for chronicdiseases. Proc Natl Acad Sci USA 2000; 97: 7482-7487.
183. Puntel M, Muhammad AK, Candolfi M, et al. A novel bicistronic high-capacity gutless adenovirus vector that drives constitutive expression of herpes simplex virus type 1 thymidine kinase and tetinducible expression of Flt3L for glioma therapeutics. J Virol 2010; 84: 6007-6017.
184. Muhammad AK, Puntel M, Candolfi M, et al. Study of the efficacy, biodistribution, and safety profile of therapeutic gutless adenovirus vectors as a prelude to a phase I clinical trial for glioblastoma. Clin Pharmacol Ther 2010; 88: 204-213.
185. Kass-Eisler A, Leinwand L, Gall J, Bloom B, Falck-Pedersen E. Circumventing the immune response to adenovirus-mediated gene therapy. Gene Ther 1996; 3: 154-162.
186. Mack CA, Song WR, Carpenter H, et al. Circumvention of antiadenovirus neutralizing immunity by administration of an adenoviral vector of an alternate serotype. Hum Gene Ther 1997; 8: 99-109.
187. Mastrangeli A, Harvey BG, Yao J, et al. Sero-switch adenovirusmediated in vivo gene transfer: circumvention of anti-adenovirus humoral immune defenses against repeat adenovirus vector administration by changing the adenovirus serotype. Hum Gene Ther 1996; 7: 79-87.
188. Parks R, Evelegh C, Graham F. Use of helper-dependent adenoviral vectors of alternative serotypes permits repeat vector administration. Gene Ther 1999; 6: 1565-1573.
189. Appledorn DM, Kiang A, McBride A, et al. Wild-type adenoviruses from groups A-F evoke unique innate immune responses, of which HAd3 and SAd23 are partially complement dependent. Gene Ther 2008; 15: 885-901.
190. Wang H, Li ZY, Liu Y, et al. Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14. Nat Med 2011; 17: 96-104.
191. Segerman A, Atkinson JP, Marttila M, et al. Adenovirus type 11 uses CD46 as a cellular receptor. J Virol 2003; 77: 9183-9191.
192. Sirena D, Lilienfeld B, Eisenhut M, et al. The human membrane cofactor CD46 is a receptor for species B adenovirus serotype 3. J Virol 2004; 78: 4454-44562.
193. Gao W, Tamin A, Soloff A, et al. Effects of a SARS-associated coronavirus vaccine in monkeys. Lancet 2003; 362: 1895-1896.
194. Reddy PS, Ganesh S, Limbach MP, et al. Development of adenovirus serotype 35 as a gene transfer vector. Virology 2003; 311: 384-393.
195. Sakurai F, Mizuguchi H, Hayakawa T. Efficient gene transfer into human CD34+ cells by an adenovirus type 35 vector. Gene Ther 2003; 10: 1041-1048.
196. Vogels R, Zuijdgeest D, van RR, et al. Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity. J Virol 2003; 77: 8263-8271.
197. Barouch DH, Pau MG, Custers JH, et al. Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of preexisting anti-Ad5 immunity. J Immunol 2004; 172: 6290-6297.
198. Shiver JW, Emini EA. Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors. Annu Rev Med 2004; 55: 355-372.
199. Sakurai F, Nakamura S, Akitomo K, et al. Transduction properties of adenovirus serotype 35 vectors after intravenous administration into nonhuman primates. Mol Ther 2008; 16: 726-733.
200. Sakurai F, Nakamura SI, Akitomo K, et al. Adenovirus serotype 35 vector-mediated transduction following direct administration into organs of nonhuman primates. Gene Ther 2009; 16: 297-302.
201. Holterman L, Vogels R, van der Vlugt R, et al. Novel replicationincompetent vector derived from adenovirus type 11 (Ad11) for vaccination and gene therapy: low seroprevalence and non-crossreactivity with Ad5. J Virol 2004; 78: 13207-13215.
202. Stone D, Ni S, Li ZY, et al. Development and assessment of human adenovirus type 11 as a gene transfer vector. J Virol 2005; 79: 5090-5104.
203. Stone D, Liu Y, Li ZY, et al. Comparison of adenoviruses from species B, C, E, and F after intravenous delivery. Mol Ther 2007; 15: 2146-2153.
204. Lemckert AA, Grimbergen J, Smits S, et al. Generation of a novel replication-incompetent adenoviral vector derived from human adenovirus type 49: manufacture on PER.C6 cells, tropism and immunogenicity. J Gen Virol 2006; 87: 2891-2896.
205. Mittal SK, Bett AJ, Prevec L, Graham FL. Foreign gene expression by human adenovirus type 5-based vectors studied using firefly luciferase and bacterial beta-galactosidase genes as reporters. Virology 1995; 210: 226-230.
206. Reddy PS, Idamakanti N, Hyun BH, Tikoo SK, Babiuk LA. Development of porcine adenovirus-3 as an expression vector. J Gen Virol 1999; 80: 563-570.
207. van Olphen AL, Tikoo SK, Mittal SK. Characterization of bovine adenovirus type 3 E1 proteins and isolation of E1-expressing cell lines. Virology 2002; 295: 108-118.
208. Bru T, Salinas S, Kremer EJ. An Update on Canine Adenovirus Type 2 and Its Vectors. Viruses-Basel 2010; 2: 2134-2153.
209. Hemminki A, Kanerva A, Kremer EJ, et al. A canine conditionally replicating adenovirus for evaluating oncolytic virotherapy in a syngeneic animal model. Mol Ther 2003; 7: 163-173.
210. Klonjkowski B, Gilardi-Hebenstreit P, Hadchouel J, et al. A recombinant E1-deleted canine adenoviral vector capable of transduction and expression of a transgene in human-derived cells and in vivo. Hum Gene Ther 1997; 8: 2103-2115.
211. Bridgeman A, Roshorm Y, Lockett LJ, et al. Ovine atadenovirus, a novel and highly immunogenic vector in prime-boost studies of a candidate HIV-1 vaccine. Vaccine 2009; 28: 474-483.
212. Hofmann C, Loser P, Cichon G, et al. Ovine adenovirus vectors overcome preexisting humoral immunity against human adenoviruses in vivo. J Virol 1999; 73: 6930-6936.
213. Farina SF, Gao GP, Xiang ZQ, et al. Replication-defective vector based on a chimpanzee adenovirus. J Virol 2001; 75: 11603-11613.
214. Xiang Z, Gao G, Reyes-Sandoval A, et al. Novel, chimpanzee serotype 68-based adenoviral vaccine carrier for induction of antibodies to a transgene product. J Virol 2002; 76: 2667-2675.
215. Patel A, Tikoo S, Kobinger G. A porcine adenovirus with low human seroprevalence is a promising alternative vaccine vector to human adenovirus 5 in an H5N1 virus disease model. PLoS One 2010; 5: e15301.
216. Reddy PS, Idamakanti N, Chen Y, et al. Replication-defective bovine adenovirus type 3 as an expression vector. J Virol 1999; 73: 9137-9144.
217. Bangari DS, Mittal SK. Current strategies and future directions for eluding adenoviral vector immunity. Curr Gene Ther 2006; 6: 215-226.
218. Bangari DS, Shukla S, Mittal SK. Comparative transduction efficiencies of human and nonhuman adenoviral vectors in human, murine, bovine, and porcine cells in culture. Biochem Biophys Res Commun 2005; 327: 960-966.
219. Rasmussen UB, Benchaibi M, Meyer V, Schlesinger Y, Schughart K. Novel human gene transfer vectors: evaluation of wild-type and recombinant animal adenoviruses in human-derived cells. Hum Gene Ther 1999; 10: 2587-2599.
220. Reyes-Sandoval A, Sridhar S, Berthoud T, et al. Single-dose immunogenicity and protective efficacy of simian adenoviral vectors against Plasmodium berghei. Eur J Immunol 2008; 38: 732-741.
221. Tatsis N, Lasaro MO, Lin SW, et al. Adenovirus vector-induced immune responses in nonhuman primates: responses to prime boost regimens. J Immunol 2009; 182: 6587-6599.
222. Sharma A, Tandon M, Ahi YS, et al. Evaluation of cross-reactive cell-mediated immune responses among human, bovine and porcine adenoviruses. Gene Ther 2010; 17: 634-642.
223. Singh N, Pandey A, Jayashankar L, Mittal S.K. Bovine adenoviral vector-based H5N1 influenza vaccine overcomes exceptionally high levels of pre-existing immunity against human adenovirus. Mol Ther 2008; 16: 965-971.
224. Sharma A, Li X, Bangari DS, Mittal SK. Adenovirus receptors and their implications in gene delivery. Virus Res 2009; 143: 184-194.